Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLG1080 in Hormone-sensitive Advanced Prostate Cancer
NCT06837896Phase 3Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Mar 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of QLG1080 in prostate cancer (PCa), sponsored by Qilu Pharmaceutical. Started Mar 2025; status: completed.
02
Drugs
QLG1080
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06837896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06837896.